Clinigene International and SCIREX Corporation to Collaborate on Global Clinical Trials

Share Article

Clinigene International, a wholly owned subsidiary of India's premier Biotech enterprise, Biocon Limited, and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group, have announced that they have signed a Letter of Intent (LOI) to collaborate on global clinical trials.

Clinigene International, a wholly owned subsidiary of India's premier Biotech enterprise, Biocon Limited, and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group, have announced that they have signed a Letter of Intent (LOI) to collaborate on global clinical trials. The LOI was signed at SCIREX’s Headquarters in Horsham, Pennsylvania, USA, during a recent visit by Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon and Dr. Arvind Atignal, Chief Operating Officer, Clinigene.

With India rapidly emerging as a key locale for clinical research, the new relationship provides SCIREX clients immediate access to well developed expertise in clinical investigation in India and provides Clinigene the opportunity to expand its markets and partake in global clinical trial programs.

"SCIREX is extremely pleased to forge a new kind of exclusive partnership in India. “We were a natural fit from the very beginning,” said SCIREX CEO Jim Utterback. “This brings our clients a best in class firm that not only offers them substantial value based on cost efficiencies and great science but also demonstrated clinical trial expertise. SCIREX and our parent, Omnicom Group, can be truly integrated research and commercialization partners with Clinigene for years to come."

Dr. Mazumdar-Shaw said that she saw the partnership as a natural evolution for Clinigene and Biocon given the “significant investment made over the past decade in systems, processes, and people. We are proud of the leading role we have taken in India and look forward to enabling SCIREX’s clients to benefit from the quality and speed of clinical development in India.”

“SCIREX’s expertise and vast experience in IND Filings and conduct of Global Clinical Trials will further position Biocon/Clinigene as a world-class clinical development organization,” added Dr. Arvind Atignal.

“At the end of the day, the CRO business is about expertise, leadership and commitment to creating value. I feel our respective companies’ personalities and cultures were a perfect fit," said Utterback.

About SCIREX

SCIREX Corporation (http://www.scirex.com) is an industry leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industry. SCIREX possesses capabilities in clinical trial management, drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions. SCIREX has experience from more than 1,000 clinical trials involving well over 130,000 patients, in pain and inflammation, neurological and psychiatric disorders, infectious diseases and gastrointestinal and cardiovascular indications. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc. (NYSE: OMC) (http://www.omnicomgroup.com). Omnicom is a leading global advertising, marketing and corporate communications company.

About Clinigene

Established in 2000, Clinigene is one of India’s leading Clinical Research Organisations that offers comprehensive clinical services from Phase 1 - Phase 4. The company maintains disease-focused patient registries and clinical databases in diabetes, lipidemia, oncology and cardiovascular diseases that enable faster study start-up and more efficient data collection due to depth and longevity of their site and investigator relationships. Clinigene’s Clinical Research Facilities are accredited by the CAP - College of American Pathologists, USA. Currently Clinigene is carrying out a Phase IIB study for Biocon Biopharmaceutical’s Monoclonal Antibody targeted against Head and Neck Cancer and is in the process of filing an IND for Biocon’s Oral Insulin.

About Biocon Group

Established in 1978, Biocon is India's premier biotechnology company with consolidated revenues in excess of USD 150 Million and a Market Capitalisation of about USD 1 Billion. Biocon and its three subsidiary companies, Syngene International Private Limited, Clinigene International Private Limited and Biocon Biopharmaceuticals Private Limited, form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in drug discovery, clinical development, bioprocessing and global marketing, Biocon delivers products and solutions to partners and customers across 70 countries. (http://www.biocon.com).

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Blythe Vito